Scientists report promising activity of a novel drug that targets a key molecular driver of clear cell renal cell carcinoma (ccRCC) in patients with metastatic disease. Researchers from Dana-Farber Cancer Institute report a response rate of 24 percent across…

Read More

Drop your comments

Click to Comment

Share this post with your friends on


COMMENTS (0)

Reply

All fields are required

Save my name for the next time I comment